Longeveron LLC (LGVN NASDAQ) stock market data APIs
$1.3422
-0.02(-1.5%)
as of May 21, 2025
Try our APIs with
free plan!
Longeveron LLC Financial Data Overview
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Prev. Close
1.3422
Open
1.327
High
1.3485
Low
1.29
52 wk Range
0.7707-6.4
Market Cap
20 112 K
Shares Outstanding
13 525 K
Revenue
2 392 K
EPS
-0.34
Beta
0.37
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Longeveron LLC data using free add-ons & libraries
Get Longeveron LLC Fundamental Data
Longeveron LLC Fundamental data includes:
- Net Revenue: 2 392 K
- EBITDA: -15 564 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-09
- EPS/Forecast: -0.3275
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Longeveron LLC News
New
Longeveron® to Attend BIO International Convention 2025
Focus on potential partnership and strategic opportunities for the Company’s stem cell therapy program for Alzheimer’s diseaseRecent Type B meeting with FDA provided alignment on a planned single,...
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapyStem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer’s disease and HLHS,...
Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ag...
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease
Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s diseaseThis encouraging clinical trial ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
